Blood:鲁索替替尼与噬血细胞综合征

2019-04-25 MedSci MedSci原创

噬红细胞性淋巴细胞与组织细胞增多症(HLH,又称噬血细胞综合征)是一种致死性疾病,特征是T细胞和巨噬细胞过度激活,产生过量的促炎细胞因子,包括干扰素-γ(IFNγ)。Sabrin Albeituni等人既往发现Janus激酶(JAK)抑制剂鲁索替尼可抑制T细胞活化,减轻HLH模型(用淋巴细胞脉络丛脑膜炎病毒[LCMV]感染穿孔素缺陷[Prf1-/-]小鼠)的炎症反应。鲁索替尼抑制IFNγ的下游信号

噬红细胞性淋巴细胞与组织细胞增多症(HLH,又称噬血细胞综合征)是一种致死性疾病,特征是T细胞和巨噬细胞过度激活,产生过量的促炎细胞因子,包括干扰素-γ(IFNγ)。

Sabrin Albeituni等人既往发现Janus激酶(JAK)抑制剂鲁索替尼可抑制T细胞活化,减轻HLH模型(用淋巴细胞脉络丛脑膜炎病毒[LCMV]感染穿孔素缺陷[Prf1-/-]小鼠)的炎症反应。鲁索替尼抑制IFNγ的下游信号和其他几个JAK依赖性的细胞因子。

但目前仍不清楚鲁索替尼用于HLH是否可通过抑制IFNγ信号或靶向由其他促炎性细胞因子激活的信号发挥有利作用。为阐明这一问题,Sabrin Albeituni等人在两种小鼠HLH模型中,对比鲁索替尼和IFNγ中和抗体(αIFNγ)的治疗效果。

在两种模型中,鲁索替尼和αIFNγ均可减轻炎症相关的贫血,提示鲁索替尼通过IFNγ依赖性方式发挥作用逆转HLH表型。相反,鲁索替尼处理的小鼠的T细胞和中性粒细胞的数量和激活状态以及组织浸润均明显减少,而αIFNγ处理的小鼠的没有变化或有所增加。

此外,即使治疗中断后,鲁索替尼治疗组的LCMV感染的Prf1-/-小鼠的存活情况仍优于αIFNγ治疗组的小鼠。上述保护作用可通过αIFNγ进而一种中性粒细胞耗竭性抗体一过性治疗模拟。

综上所述,鲁索替尼通过IFNγ依赖性和非依赖性机制发挥作用,通过靶向毒性效应T细胞/中性粒细胞缓解HLH。

原始出处:

Sabrin Albeituni, et al. Mechanisms of Action of Ruxolitinib in Murine Models of Hemophagocytic Lymphohistiocytosis. Blood 2019 :blood.2019000761; doi: https://doi.org/10.1182/blood.2019000761 

本文系williamhill asia 医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681853, encodeId=144416818531f, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Nov 22 03:57:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283854, encodeId=e9b7128385452, content=<a href='/topic/show?id=886c4035e5d' target=_blank style='color:#2F92EE;'>#噬血细胞综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40357, encryptionId=886c4035e5d, topicName=噬血细胞综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Apr 27 12:57:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431502, encodeId=40c014315021a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Apr 27 12:57:00 CST 2019, time=2019-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681853, encodeId=144416818531f, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Nov 22 03:57:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283854, encodeId=e9b7128385452, content=<a href='/topic/show?id=886c4035e5d' target=_blank style='color:#2F92EE;'>#噬血细胞综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40357, encryptionId=886c4035e5d, topicName=噬血细胞综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Apr 27 12:57:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431502, encodeId=40c014315021a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Apr 27 12:57:00 CST 2019, time=2019-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681853, encodeId=144416818531f, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Nov 22 03:57:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283854, encodeId=e9b7128385452, content=<a href='/topic/show?id=886c4035e5d' target=_blank style='color:#2F92EE;'>#噬血细胞综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40357, encryptionId=886c4035e5d, topicName=噬血细胞综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Apr 27 12:57:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431502, encodeId=40c014315021a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Apr 27 12:57:00 CST 2019, time=2019-04-27, status=1, ipAttribution=)]

相关威廉亚洲官网

FDA授予Jakavi(鲁索替尼)治疗急性移植物抗宿主病(GVHD)的突破性药物资格

Incyte制药公司近日宣布,美国食品和药物管理局(FDA)已授予Jakavi(ruxolitinib,鲁索替尼)治疗急性移植物抗宿主病(graft-versus-host disease,GVHD)的突破性药物资格(BTD)。移植物抗宿主病(GVHD)是由于移植物的抗宿主反应而引起的一种免疫性疾病,是异基因造血干细胞移植的主要并发症和造成死亡的主要原因。GVHD患者最常见的受累器官为皮肤、胃